Kits and reagents account for the majority of market revenue. Their dominance is driven by their essential role in both academic research and clinical diagnostics, offering high specificity and compatibility with next-generation sequencing (NGS) platforms.
While DNA methylation is the established standard, RNA methylation is emerging as a high-growth niche due to the burgeoning field of RNA-based therapeutics, including mRNA vaccines and RNAi therapies. RNA methylation analysis is critical for ensuring the stability, efficiency, and translational relevance of these drugs.
The life sciences industry is undergoing a paradigm shift where methylation of DNA and RNA serves as a vital biomarker for oncology, neurology, and cardiovascular diseases. This enables the development of targeted therapeutics and companion diagnostics, allowing for treatments tailored to individual genomic profiles.
Asia-Pacific is identified as the fastest-growing region. This growth is fueled by large-scale government-led genomics projects, expanding pharmaceutical manufacturing in countries like China, India, and South Korea, and increasing investments in healthcare infrastructure.
Methylation-based assays are gaining significant traction in clinical settings due to their non-invasive nature. They are increasingly integrated into liquid biopsy workflows for early-stage cancer detection, tumor monitoring, and predicting treatment responses through DNA methylation signatures.
The primary bottleneck is the lack of global standardization and cross-platform reproducibility. Variations in bisulfite conversion efficiency, sequencing platforms, and bioinformatic pipelines complicate data interpretation, which is a critical requirement for regulatory validation and use in low-resource settings.
Next-generation sequencing (NGS), specifically whole-genome bisulfite sequencing and methylation-specific PCR-based techniques, remains the leading technology. Recent advancements, such as Illumina’s NovaSeq X Plus, have further enhanced throughput and capacity for oncology and rare disease research.
Regulatory backing is a major growth catalyst. Official recognition and fast-tracking of methylation-based diagnostic assays by the FDA and EMA provide companies with more favorable avenues for clinical test approvals, encouraging broader adoption in routine clinical practice.
Key developments include Illumina’s launch of the NovaSeq X Plus system (June 2024), Thermo Fisher’s introduction of MethylSeq Pro Enzymatic Kits for liquid biopsies (February 2024), and Merck KGaA’s acquisition of Epify Technologies (May 2023) to enhance its clinical epigenomics pipeline.
